Back to search

Article

Effects of EGFR, FGFR2, and MET Gene Copy Number Variation Status on the Efficacy of Pelitinib, Tepotinib, and Docetaxel in Gastric Cancer Cell Lines

2026-05-19

Abstract excerpt

Amplification of the mesenchymal–epithelial transition factor protooncogene (MET), fibroblast growth factor receptor 2 (FGFR2), and epidermal growth factor receptor (EGFR) genes has been identified in 2–24%, 2–9%, and 27–64% of patients with gastric cancer (GC), respectively. This study characterised carcinogenesis-related alterations and copy number variation (CNV) in 286 genes from four human GC cell lines and a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ee7223ee-218d-539b-ba48-04726ec9b6a4
DOI
10.20944/preprints202605.1177.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effects of EGFR, FGFR2, and MET Gene Copy Number Variation Status on the Efficacy of Pelitinib, Tepotinib, and Docetaxel in Gastric Cancer Cell LinesDOI 10.20944/preprints202605.1177.v1
Comparison of the Efficacy of 35 Anticancer Drugs According to Genomic Profiling and Biological Characteristics of 14 Gastric Cancer Cell LinesSemantic proximity
Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft modelsSemantic proximity
Precision oncology for RET-related tumorsSemantic proximity
MET-amplified gastric cancers exhibit co-amplifications of BRAF, CDK6, and EGFR.Semantic proximity
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.Semantic proximity
Efficacy and Safety of targeted therapy Inhibitors for RET-driven Solid Cancer: A Systematic Review and Meta-analysisSemantic proximity
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.Semantic proximity
GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors.Semantic proximity
Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.Semantic proximity
Forty‐nine gastric cancer cell lines with integrative genomic profiling for development of c‐MET inhibitorSemantic proximity
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with TrastuzumabSemantic proximity
Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer.Semantic proximity
Select a neighboring publication to make it the new centre.